Amgen AMGN announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status. Blincyto, a first-in-class ...
Source LinkAmgen AMGN announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status. Blincyto, a first-in-class ...
Source Link
Comments